JPWO2021067696A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021067696A5 JPWO2021067696A5 JP2022520473A JP2022520473A JPWO2021067696A5 JP WO2021067696 A5 JPWO2021067696 A5 JP WO2021067696A5 JP 2022520473 A JP2022520473 A JP 2022520473A JP 2022520473 A JP2022520473 A JP 2022520473A JP WO2021067696 A5 JPWO2021067696 A5 JP WO2021067696A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- methyl
- octahydrocyclopenta
- pyran
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003839 salts Chemical class 0.000 claims description 56
- 150000001875 compounds Chemical class 0.000 claims description 53
- SDZSYMDSAMUDHX-UHFFFAOYSA-N thieno[2,3-d]pyridazin-4-amine Chemical compound NC1=NN=CC2=C1C=CS2 SDZSYMDSAMUDHX-UHFFFAOYSA-N 0.000 claims description 29
- 125000000623 heterocyclic group Chemical group 0.000 claims description 24
- 125000000217 alkyl group Chemical group 0.000 claims description 21
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims description 12
- ZYECVHNCKVTVSA-UHFFFAOYSA-N thieno[2,3-d]pyridazin-7-amine Chemical compound NC1=NN=CC2=C1SC=C2 ZYECVHNCKVTVSA-UHFFFAOYSA-N 0.000 claims description 12
- -1 2-oxaspiro[3.3]heptanyl Chemical group 0.000 claims description 11
- 229910052736 halogen Inorganic materials 0.000 claims description 10
- 229910052739 hydrogen Inorganic materials 0.000 claims description 10
- 239000001257 hydrogen Substances 0.000 claims description 10
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 10
- 125000006645 (C3-C4) cycloalkyl group Chemical group 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 208000035475 disorder Diseases 0.000 claims description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 8
- 125000003118 aryl group Chemical group 0.000 claims description 8
- 150000002367 halogens Chemical class 0.000 claims description 8
- 125000001072 heteroaryl group Chemical group 0.000 claims description 8
- 201000000980 schizophrenia Diseases 0.000 claims description 8
- 125000001424 substituent group Chemical group 0.000 claims description 8
- 229910052757 nitrogen Inorganic materials 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- UZHVXJZEHGSWQV-UHFFFAOYSA-N 1,2,3,3a,4,5,6,6a-octahydrocyclopenta[c]pyrrole Chemical compound C1NCC2CCCC21 UZHVXJZEHGSWQV-UHFFFAOYSA-N 0.000 claims description 5
- 208000016285 Movement disease Diseases 0.000 claims description 5
- 125000002947 alkylene group Chemical group 0.000 claims description 5
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 5
- 125000005842 heteroatom Chemical group 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 206010008748 Chorea Diseases 0.000 claims description 4
- 208000028698 Cognitive impairment Diseases 0.000 claims description 4
- 208000007590 Disorders of Excessive Somnolence Diseases 0.000 claims description 4
- 208000012661 Dyskinesia Diseases 0.000 claims description 4
- 208000014094 Dystonic disease Diseases 0.000 claims description 4
- 208000023105 Huntington disease Diseases 0.000 claims description 4
- 208000018737 Parkinson disease Diseases 0.000 claims description 4
- 206010034010 Parkinsonism Diseases 0.000 claims description 4
- 206010041349 Somnolence Diseases 0.000 claims description 4
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims description 4
- 208000000323 Tourette Syndrome Diseases 0.000 claims description 4
- 208000016620 Tourette disease Diseases 0.000 claims description 4
- 150000004945 aromatic hydrocarbons Chemical class 0.000 claims description 4
- 125000004452 carbocyclyl group Chemical group 0.000 claims description 4
- 206010008129 cerebral palsy Diseases 0.000 claims description 4
- 208000012601 choreatic disease Diseases 0.000 claims description 4
- 208000010877 cognitive disease Diseases 0.000 claims description 4
- 208000010118 dystonia Diseases 0.000 claims description 4
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims description 4
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 3
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 3
- 208000014644 Brain disease Diseases 0.000 claims description 3
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 claims description 3
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 3
- 229910052760 oxygen Inorganic materials 0.000 claims description 3
- 229910052717 sulfur Inorganic materials 0.000 claims description 3
- 230000008485 antagonism Effects 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000005843 halogen group Chemical group 0.000 claims description 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims description 2
- 125000003566 oxetanyl group Chemical group 0.000 claims description 2
- 208000024891 symptom Diseases 0.000 claims description 2
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 2
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 claims description 2
- 229930192474 thiophene Natural products 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 7
- 125000004008 6 membered carbocyclic group Chemical group 0.000 claims 3
- 150000000022 5-membered heteroarenes Chemical class 0.000 claims 2
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 1
- 150000000025 6-membered heteroarenes Chemical class 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 150000001924 cycloalkanes Chemical class 0.000 claims 1
- 150000002390 heteroarenes Chemical class 0.000 claims 1
- WTYSCLHDMXBMKM-UHFFFAOYSA-N phthalazin-1-amine Chemical compound C1=CC=C2C(N)=NN=CC2=C1 WTYSCLHDMXBMKM-UHFFFAOYSA-N 0.000 claims 1
- 238000000034 method Methods 0.000 description 10
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962910863P | 2019-10-04 | 2019-10-04 | |
| US62/910,863 | 2019-10-04 | ||
| PCT/US2020/053942 WO2021067696A1 (en) | 2019-10-04 | 2020-10-02 | Antagonists of the muscarinic acetylcholine receptor m4 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022550459A JP2022550459A (ja) | 2022-12-01 |
| JPWO2021067696A5 true JPWO2021067696A5 (https=) | 2023-10-11 |
| JP2022550459A5 JP2022550459A5 (https=) | 2023-10-11 |
| JP7572734B2 JP7572734B2 (ja) | 2024-10-24 |
Family
ID=75337550
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022520473A Active JP7572734B2 (ja) | 2019-10-04 | 2020-10-02 | ムスカリン性アセチルコリン受容体ｍ４のアンタゴニスト |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US12319701B2 (https=) |
| EP (1) | EP4037677B1 (https=) |
| JP (1) | JP7572734B2 (https=) |
| AU (1) | AU2020358000A1 (https=) |
| CA (1) | CA3155864A1 (https=) |
| ES (1) | ES3057371T3 (https=) |
| WO (1) | WO2021067696A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12600726B2 (en) | 2017-07-12 | 2026-04-14 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor M4 |
| IL310346A (en) | 2017-10-20 | 2024-03-01 | Univ Vanderbilt | Muscarinic acetylcholine M4 receptor antagonists |
| US20230183218A1 (en) * | 2020-04-24 | 2023-06-15 | Vanderbilt University | Condensed substituted hydropyrroles as antagonists of the muscarinic acetylcholine receptor m4 |
| US20240174655A1 (en) * | 2021-04-02 | 2024-05-30 | Vanderbilt University | Indazole derivatives as antagonists of the muscarinic acetylcholine receptor m4 |
| US20240287050A1 (en) * | 2021-06-11 | 2024-08-29 | Vanderbilt University | (4-(6-((2-octahydrocyclopenta[c]pyrrol-5-yl)amino)pyridazin-3-yl)phenyl)(imino)(methyl)-lambda6- sulfanone derivatives and similar compounds as muscarinic acetylcholine receptor m4 antagonists for the treatment of neurodegenerative disorders |
| MX2024000984A (es) | 2021-07-21 | 2024-06-19 | Nico Therapeutics Inc | Compuesto de piridazina anilado. |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2007208351C1 (en) | 2006-01-23 | 2011-07-07 | Amgen Inc. | Aurora kinase modulators and method of use |
| US7560551B2 (en) | 2006-01-23 | 2009-07-14 | Amgen Inc. | Aurora kinase modulators and method of use |
| EP2038289A2 (en) | 2006-04-21 | 2009-03-25 | Amgen Inc. | Thieno-[2,3-d]pyrimidine and thieno-pyridazine compounds and methods of use |
| US8691865B2 (en) | 2008-11-26 | 2014-04-08 | Abbvie Inc. | Substituted octahydrocyclopenta[C]pyrrol-4-amines as calcium channel blockers |
| WO2015027204A1 (en) * | 2013-08-23 | 2015-02-26 | Vanderbilt University | Substituted thieno[2,3-b]pyridine-2-carboxamide analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m4 |
| KR20180110132A (ko) * | 2016-02-16 | 2018-10-08 | 반더빌트유니버시티 | 무스카린성 아세틸콜린 수용체 m1의 양성 알로스테릭 조절제 |
| MX389592B (es) * | 2016-09-02 | 2025-03-20 | Suven Life Sciences Ltd | Moduladores alostericos positivos del receptor m1 muscarinico |
| US12600726B2 (en) * | 2017-07-12 | 2026-04-14 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor M4 |
| IL310346A (en) | 2017-10-20 | 2024-03-01 | Univ Vanderbilt | Muscarinic acetylcholine M4 receptor antagonists |
| AU2018360581A1 (en) | 2017-10-31 | 2020-06-11 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor M4 |
| CN111788182B (zh) | 2018-02-02 | 2023-09-26 | 范德堡大学 | 毒蕈碱性乙酰胆碱受体m4的拮抗剂 |
| AU2020402978A1 (en) | 2019-12-10 | 2022-06-23 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor M4 |
| JP2023506740A (ja) | 2019-12-10 | 2023-02-20 | ヴァンダービルト ユニバーシティー | ムスカリン性アセチルコリン受容体ｍ４のアンタゴニスト |
| US20230183218A1 (en) | 2020-04-24 | 2023-06-15 | Vanderbilt University | Condensed substituted hydropyrroles as antagonists of the muscarinic acetylcholine receptor m4 |
| EP4139303A1 (en) | 2020-04-24 | 2023-03-01 | Vanderbilt University | Condensed substituted hydropyrroles as antagonists of the muscarinic acetylcholine receptor m4 |
| AU2021381350A1 (en) | 2020-11-18 | 2023-06-08 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor m4 |
| IL303774A (en) | 2020-12-22 | 2023-08-01 | Univ Vanderbilt | M4 muscarinic acetylcholine receptor antagonists |
| CN116669737A (zh) | 2020-12-22 | 2023-08-29 | 范德堡大学 | 毒蕈碱型乙酰胆碱受体m4的拮抗剂 |
| US20240174655A1 (en) | 2021-04-02 | 2024-05-30 | Vanderbilt University | Indazole derivatives as antagonists of the muscarinic acetylcholine receptor m4 |
| US20240228468A1 (en) | 2021-04-05 | 2024-07-11 | Vanderbilt University | N-(6-((octahydrocyclopenta[c]pyrrol-5-yi)amino)pyridazin-3-yl)phenyl)carboxamide and (6- ((octahydrocyclopenta[c]pyrrol-5-yl)amino)pyridazin-3-yl)benzamide derivatives as machr m4 antagonists for the treatment of neurodegenerative disorders |
| US20240287050A1 (en) | 2021-06-11 | 2024-08-29 | Vanderbilt University | (4-(6-((2-octahydrocyclopenta[c]pyrrol-5-yl)amino)pyridazin-3-yl)phenyl)(imino)(methyl)-lambda6- sulfanone derivatives and similar compounds as muscarinic acetylcholine receptor m4 antagonists for the treatment of neurodegenerative disorders |
-
2020
- 2020-10-02 AU AU2020358000A patent/AU2020358000A1/en active Pending
- 2020-10-02 JP JP2022520473A patent/JP7572734B2/ja active Active
- 2020-10-02 EP EP20873262.8A patent/EP4037677B1/en active Active
- 2020-10-02 CA CA3155864A patent/CA3155864A1/en active Pending
- 2020-10-02 US US17/766,341 patent/US12319701B2/en active Active
- 2020-10-02 WO PCT/US2020/053942 patent/WO2021067696A1/en not_active Ceased
- 2020-10-02 ES ES20873262T patent/ES3057371T3/es active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI680128B (zh) | 二氫吡咯並吡啶衍生物 | |
| JP2023530320A (ja) | Ｎａｖ１．８阻害剤としての５－オキソピロリジン－３－カルボキサミド | |
| JP6505023B2 (ja) | Ｃｎｓおよび他の障害を治療するための、ｐｄｅ４アイソザイムの阻害薬としてのアザベンゾイミダゾール化合物 | |
| JP5743901B2 (ja) | 皮膚疾患の処置のためのホスホジエステラーゼ阻害薬としてのトリアゾロピリジン誘導体 | |
| JP2023523640A (ja) | ベンゾチアゾリルビアリール系化合物、その調製方法及び使用 | |
| AU2026200630A1 (en) | Substituted cycloalkyls as modulators of the integrated stress pathway | |
| ES2399314T3 (es) | Gamma lactamas sustituidas como agentes terapeúticos | |
| ES2380395T3 (es) | Triazolopiridinas como inhibidores de fosfodiesterasa para el tratamiento de enfermedades dérmicas | |
| CN109641898A (zh) | 用于治疗神经和神经退行性疾病的5,7-二氢-吡咯并-吡啶衍生物 | |
| JP5439377B2 (ja) | ヒスタミンｈ４受容体のチエノ−及びフロ−ピリミジン調節物質 | |
| RU2017118165A (ru) | Ингибиторы энхансера гомолога 2 zestes | |
| JP7611154B2 (ja) | ピリド－ピリミジニル化合物及び使用の方法 | |
| JP2014528433A5 (https=) | ||
| JP2011105735A (ja) | タンパク質チロシンキナーゼ活性の阻害剤 | |
| CA3191001A1 (en) | Synthesis of quinazoline compounds | |
| TW202003491A (zh) | 哌嗪氮雜螺衍生物 | |
| WO2016009297A1 (en) | Pyridine derivatives as muscarinic m1 receptor positive allosteric modulators | |
| RU2015144385A (ru) | Ациклические цианоэтилпиразолопиридоны в качестве ингибиторов янус-киназы | |
| KR20170040299A (ko) | 이미다조피리다진 화합물 | |
| TW202003487A (zh) | 經取代的２，２＇—聯嘧啶基化合物、其類似物及其使用方法 | |
| MXPA05005580A (es) | Derivados de isoindolina. | |
| RU2712455C1 (ru) | 6,7,8,9-тетрагидро-5h-пиридо[2,3-d]азепиновые лиганды дофаминовых рецепторов d3 | |
| RU2012109220A (ru) | Новые соединения и их терапевтическое использование для ингибирования протеинкиназы | |
| JP2011526911A (ja) | ベンゾイミダゾール−２−イルピリミジン誘導体を製造する方法 | |
| WO2025090516A1 (en) | Methods of preparing compounds for treating pain and solid forms thereof |